Squamous cell carcinoma (SCC) of the bladder is a distinct and rarer form, accounting for approximately 2% to 5% of all bladder cancers in the U.S. It develops in the flat, thin squamous cells that ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to DPTX3186, a first in class oral condensate ...

Sometimes, lung cancer can show itself in unexpected ways through the skin. While these skin symptoms are less common, they ...

The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

Many dedicated dog parents like @hayleyglatfelter know what it's like to rehabilitate a sick dog, but this brave woman has seen her even braver pup, Gideon, endure so much this year. Earlier this fall ...

Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.

Combined healthy eating and exercise more effectively reduce harmful visceral fat, study showsWhen it comes to keeping that ...

Clinical trials for cancer can help doctors discover better treatments and improve the quality of life for patients.

Pivotal Trend Service Co., Ltd. ("PTS") today announced the official launch of its flagship digital asset product, PMN (Pivotal Mining Note), on Republic, marking a significant milestone for the ...